When.com Web Search

  1. Ads

    related to: abbv stock dividend history data

Search results

  1. Results From The WOW.Com Content Network
  2. Is AbbVie Stock a Buy? - AOL

    www.aol.com/finance/abbvie-stock-buy-104800405.html

    Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...

  3. AbbVie - Wikipedia

    en.wikipedia.org/wiki/AbbVie

    In June, Abbvie acquired TeneoOne and its lead compound TNB-383B. The compound is a BCMA-targeting immunotherapeutic for relapsed or refractory multiple myeloma. [30] In March 2022, AbbVie acquired Syndesi Therapeutics for up to $1 billion and its portfolio of novel modulators of the synaptic vesicle protein 2A and lead compound SDI-118.

  4. Beat the Nasdaq With This Cash-Gushing Dividend Stock - AOL

    www.aol.com/beat-nasdaq-cash-gushing-dividend...

    ABBV Total Return Level data by YCharts. The lesson: AbbVie's business is strong. The company's dividend program makes the stock that much more attractive and capable of delivering superior ...

  5. Can AbbVie Regain Its Status As a Top Dividend Growth Stock?

    www.aol.com/abbvie-regain-status-top-dividend...

    ABBV Dividend Growth (Annual) data by YCharts. Despite the slowdown, AbbVie's current dividend yield of 3.19% remains attractive. This yield slightly exceeds the average of 3.12% among its big ...

  6. S&P 500 Dividend Aristocrats - Wikipedia

    en.wikipedia.org/wiki/S&P_500_Dividend_Aristocrats

    The S&P 500 Dividend Aristocrats is a stock market index composed of the companies in the S&P 500 index that have increased their dividends in each of the past 25 consecutive years. It was launched in May 2005.

  7. 2 Dividend Stocks to Buy Hand Over Fist in November - AOL

    www.aol.com/2-dividend-stocks-buy-hand-151500420...

    Let's consider two excellent options: AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN). 1. AbbVie. AbbVie continues to recover from one of the biggest patent cliffs in the pharmaceutical industry's ...